Merck signs co-promotion agreement of ‘Glucophage & Concor’ with Yungjin Pharm
The Merck Korea’s biopharma department, a Korean subsidiary of Merck, signed a Korean co-promotion agreement of the primary treatment for diabetes type 2 ‘Glucophage/ Glucophage XR’ and the selective beta blocker ‘Concor’ with Yungjin Pharm on the 13th.
Glucophage/ Glucophage XR(generic name: me...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
